The technology developed by the N2B-Patch Project may also be suitable for the use of different pharmaceutical ingredients.

The envisaged direct drug delivery platform may also support the treatment of other demyelinating disorders and other central nervous system indications, e.g. stroke, neurodegenerative diseases or tumours.

The scale-up and Good Manufacturing Practice (GMP) utilised during the development of this drug delivery platform may also be exploited to reduce time and cost to market and to also provide wider options to the patient.